高级检索
当前位置: 首页 > 详情页

CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [a]Cangzhou Clinical Medical College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Hebei, China [b]Department of Emergency, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China [c]Department ofChinese Medicine, Qingdao No. 6 People’s Hospital, Qingdao, China
出处:
ISSN:

关键词: C-X-C motif chemokine ligand 14 hepatocellular carcinoma Akt mTOR pathway apoptosis

摘要:
C-X-C motif chemokine ligand 14 (CXCL14) has antitumor effect. Kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is activated in various tumors. The relationship between CXCL14 and Akt/mTOR pathway in hepatocellular carcinoma (HCC) remained elusive. Therefore, this paper aimed to examine their interaction in HCC. First, CXCL14 expression was determined to be low-expressed in HCC tissues and cells (SNU-423, SNU-182, SNU-387, PLC/PRF/5, HuH7, and HCCLM3). Then, CXCL14 was overexpressed in HuH7 cells and inhibited in HCCLM3 cells to help investigate the function of CXCL14 on cell viability, growth and apoptosis. Akt activator (SC79) and inhibitor (AZD5363) were used to examine the involvement of Akt pathway in hepatocellular carcinoma. Overexpressed CXCL14 suppressed cell viability and growth, but promoted the apoptosis by upregulated Bax and cleaved(C) caspase-3, donwregulated Bcl-2 and the inhibition of Akt and mTOR phosphorylation. Meanwhile, knockdown of CXCL14 imposed an opposite effect to overexpressed CXCL14. SC79 partially mitigated the functions of overexpressed CXCL14, while AZD5363 mitigated the functions of CXCL14 knockdown. To conclude, CXCL14 inhibited growth but promoted apoptosis of HCC cells via suppressing Akt/mTOR pathway, thus, CXCL14 might be a potential target for HCC treatment in clinical practice.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 生物
小类 | 4 区 生化与分子生物学 4 区 细胞生物学
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 生化与分子生物学 4 区 细胞生物学
JCR分区:
出版当年[2019]版:
Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Q4 CELL BIOLOGY
最新[2023]版:
Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [a]Cangzhou Clinical Medical College of Integrated Traditional Chinese and Western Medicine, Hebei Medical University, Hebei, China
通讯作者:
通讯机构: [c]Department ofChinese Medicine, Qingdao No. 6 People’s Hospital, Qingdao, China [*1]Department of Chinese Medicine, Qingdao No. 6 People’s Hospital, No. 9 Fushun Road, Shibei District, 26000, Qingdao, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号